C4 Therapeutics, Inc.CCCCNASDAQ
Loading
CCCC Revenue Growth (YoY Quarterly)•+112.79%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+112.79%
+139.7pp
+170.01%
+185.6pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+17.40%
+13.2pp
+17.40%
+13.2pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +58.75% | +138.17% | -46.17% | -26.90% | +112.79% |
| Gross Profit Growth | +117.26% | +138.17% | -35.12% | -15.60% | +170.01% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +37.86% | +3.51% | +3.19% | +4.22% | +17.40% |
| Weighted Average Shares Diluted Growth | +37.86% | +3.51% | +3.19% | +4.22% | +17.40% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -73.71% | -40.97% | +84.92% | -36.74% | -22.60% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -7.13% | -19.79% | -22.19% | -29.40% | +2.71% |
| Book Value per Share Growth | -36.34% | -27.01% | -31.72% | -38.94% | +1.19% |
| Debt Growth | -7.35% | -7.68% | -8.03% | -8.39% | -8.78% |
| R&D Expense Growth | +6.98% | +20.14% | +10.29% | -18.37% | -23.16% |
| SG&A Expenses Growth | +20.53% | -9.31% | -9.57% | -24.20% | -11.51% |
1 / 4